/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Pain is a moderately active landscape with 45 programs across 44 companies. The most active players are Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Tanabe Pharma America, Inc.. 5 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Bubble size = clinical trials
Key Players
Pipeline
Analysis
95%
Small molecule
40 of 42 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 96% of 45 pipeline programs.
Analysis
364
clinical trials
Clinical Trials
364 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)